Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format
frozen
Type Strain
no
Genotype
MATalpha ilv5 ura3 leu2::hisG CMP2-1 [rho-0]
RefArndt C, et al. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. Microbiology 145: 1989-2000, 1999. PubMed: 10463165
Preceptrol®
no
Mating Type
alpha
RefArndt C, et al. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. Microbiology 145: 1989-2000, 1999. PubMed: 10463165
Morphology
Cells are globose, ovoidal or elongate, (3.0-8.0) x (5.0-10.0) μm, isolated or in small groups.? Sediment is present after one month.? Growth is butyrous and light cream colored.? Pseudohyphae are either not formed or are rudimentary.
Medium
ATCC® Medium 1245: YEPD
Growth Conditions
Temperature: 25.0°C
Sequenced Data
No DNA sequencing was performed in house on this product.
Name of Depositor
J Heitman
Special Collection
NCRR Contract
Isolation
derived from existing strain
References
Arndt C, et al. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. Microbiology 145: 1989-2000, 1999. PubMed: 10463165
mutant derived from strain IL993/5c, ATCC MYA-559
Arndt C, et al. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. Microbiology 145: 1989-2000, 1999. PubMed: 10463165
Arndt C, et al. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. Microbiology 145: 1989-2000, 1999. PubMed: 10463165